Sustained-Release Drug Delivery System in the Management of Glaucoma

CME | CNE 1.25 Credits

Webcast

Time to Complete: 75 minutes

Released: March 15, 2023

Expires: March 15, 2024

Maximum Credits:
1.25 / AMA PRA Category 1 Credits^TM
1.25 / ANCC Contact Hours

Program Description

A glaucoma is a heterogeneous group of diseases that has become a significant cause of irreversible blindness worldwide. A glaucoma group of optic neuropathies is characterized by progressive degeneration of retinal ganglion cells. These are central nervous system neurons with cell bodies in the inner retina and axons in the optic nerve. Degeneration of these nerves results in cupping, a characteristic optic disc appearance, and visual loss. The biological basis of glaucoma is poorly understood, and the factors contributing to its progression have not been fully characterized.

Intended Audience

Ophthalmologists, retina specialists, physician assistants and nurse practitioners in Ophthalmology clinics

Commercial Supporter

This activity is supported by an educational grant from AbbVie Inc.

Educational Objectives

Upon completion of the educational activity, participants should be able to:

• Summarize the pathophysiology of glaucoma development
• Assess clinical trial data on new sustained-release drug delivery system in the management of glaucoma

Accredited Providers

This activity is provided by Amedco, a CME/CE company, and MedNet.

      

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MedNet, LLC. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME) Credit Designation

Designation Statement

Amedco LLC designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) Credit Designation

Designation Statement

Amedco LLC designates this enduring material activity for a maximum of 1.25 ANCC contact hours.

Additional Credit Information

Note to Physician Assistants
AAPA accepts AMA PRA Category 1 Credit(s)^TM for the PRA from organizations accredited by ACCME. Maximum of 1.25 hours.

Note to Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. Maximum of 1.25 hours.

Conflicts of Interest Policy

It is the policy of the Amedco to ensure activity content is balanced, independent, objective and based on scientific best-evidence. All persons in a position to control content (i.e., course director, planning committee member and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation.

Every person in a position to control content reported he/she does not have any relevant financial relationships with industry (relative to the content of his/her presentation) to disclose.

Planners’ and Managers’ Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:

Kamatham A. Naidu, PhD (MedNet) has no relevant financial relationships.
Brian Waggoner (MedNet) has no relevant financial relationships to disclose.
Sheryl Morgan (Amedco) has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

It is the policy of the Amedco to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved) and of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Each speaker reported he/she will notify the audience if/when discussion includes off-label, unlabeled, experimental, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation.

Disclaimer

The information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Non-Endorsement of Products

Amedco do not imply either real or implied endorsement of any product, service, or company referred to in this educational activity.